

Harvey D White

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1298926/harvey-d-white-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

440
papers

47,411
citations

89
h-index

214
g-index

474
ext. papers

56,395
ext. citations

10.4
avg, IF

7.02
L-index

#	Paper	IF	Citations
440	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. <i>Diabetologia</i> , 2022 , 65, 101-112	10.3	1
439	Type 2 MI and Myocardial Injury in the Era of High-sensitivity Troponin.. <i>European Cardiology Review</i> , 2022 , 17, e03	3.9	0
438	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.. <i>Journal of the American Heart Association</i> , 2022 , e020745	6	3
437	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS121011069	6	0
436	Common genetic variants do not predict recurrent events in coronary heart disease patients.. <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 96	2.3	0
435	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.. <i>Lancet Diabetes and Endocrinology</i> , 2022 ,	18.1	4
434	Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.. <i>American Heart Journal</i> , 2022 , 251, 1-1	4.9	1
433	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120010390	6	0
432	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. <i>Circulation</i> , 2021 , 143, 790-804	16.7	21
431	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021 , 233, 92-101	4.9	4
430	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20
429	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
428	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2021 , 143, 1109-1122	16.7	16
427	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021 , 290, 392-403	10.8	4
426	Myocardial Infarction and Evolocumab. <i>JAMA Cardiology</i> , 2021 , 6, 1220-1221	16.2	1
425	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 33-43	3.9	10
424	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021 , 99, 926-939	9.9	6

4 ²³	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021 , 18, e1003513	11.6	14
4 ²²	High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. <i>BMJ, The</i> , 2021 , 372, n355	5.9	3
4 ²¹	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
4 ²⁰	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
4 ¹⁹	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
4 ¹⁸	Cardiac death should be the primary endpoint for revascularization trials and meta-analyses. <i>European Heart Journal</i> , 2021 , 42, 4697-4698	9.5	2
4 ¹⁷	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1023-1031	16.2	1
4 ¹⁶	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2021 ,	9.5	4
4 ¹⁵	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. <i>European Heart Journal</i> , 2021 ,	9.5	4
4 ¹⁴	The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55). <i>The Lancet Regional Health - Western Pacific</i> , 2020 , 5, 100056	5	9
4 ¹³	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2297-2308	15.1	23
4 ¹²	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. <i>Heart Lung and Circulation</i> , 2020 , 29, 1749-1757	1.8	0
4 ¹¹	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 1395-1407	59.2	642
4 ¹⁰	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , 2020 , 141, 1608-1617	16.7	52
4 ⁰⁹	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
4 ⁰⁸	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020 , 222, 157-165	4.9	10
4 ⁰⁷	Impact of guideline-recommended versus non-guideline-recommended β -blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 8	2.3	
4 ⁰⁶	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020 , 10, 6169	4.9	8

405	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
404	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020 , 41, 2248-2258	9.5	29
403	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020 , 41, 4245-4255	9.5	44
402	Clinically Important Improvements in Risk Assessment by Adding High-Sensitivity Troponin Level to Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020 , 5, 1263-1264	16.2	2
401	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006582	5.8	2
400	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020 , 41, 4114-4123	9.5	12
399	In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 26-33	4.3	
398	Prescribing Performance Post-Acute Coronary Syndrome Using a Composite Medication Indicator: ANZACS-QI 24. <i>Heart Lung and Circulation</i> , 2020 , 29, 824-834	1.8	0
397	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels American Heart Journal, 2020 , 225, 97-107	4.9	1
396	Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26). <i>New Zealand Medical Journal</i> , 2020 , 133, 21-40	0.8	1
395	Outcomes after ST-elevation myocardial infarction presentation to hospitals with or without a routine primary percutaneous coronary intervention service (ANZACS-QI 46). <i>New Zealand Medical Journal</i> , 2020 , 133, 64-81	0.8	0
394	Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019 , 18, 116	8.7	9
393	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1177-1186	15.1	33
392	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 1578-1589	16.7	24
391	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. <i>Physiological Genomics</i> , 2019 , 51, 506-515	3.6	2
390	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019 , 218, 57-65	4.9	3
389	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019 , 393, 407-415	40	300
388	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019 , 40, 2801-2809	9.5	27

387	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019 , 51, 957-972	36.3	217
386	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2819-2828	15.1	34
385	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 103-112	16.7	72
384	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019 , 8, e010641	6	10
383	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007445	6	
382	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 273-286	16.2	65
381	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851
380	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1167-1176	15.1	87
379	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019 , 42, 797	3.3	2
378	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
377	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
376	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019 , 140, 2054-2062	16.7	41
375	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019 , 51, 452-469	36.3	44
374	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019 , 208, 65-73	4.9	7
373	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019 , 278, 217-222	3.2	3
372	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 430-437	3.8	3
371	The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. <i>American Heart Journal</i> , 2019 , 208, 11-20	4.9	30
370	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 387-396	15.1	96

369	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G372-G386	5.1	4
368	Adjunctive antithrombotic therapy with primary percutaneous coronary intervention in ST elevation myocardial infarction: ATOLL in perspective. <i>European Heart Journal</i> , 2019 , 40, e4-e7	9.5	3
367	All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. <i>Heart Lung and Circulation</i> , 2019 , 28, 245-256	1.8	11
366	Acute reperfusion for ST-elevation myocardial infarction in New Zealand (2015-2017): patient and system delay (ANZACS-QI 29). <i>New Zealand Medical Journal</i> , 2019 , 132, 41-59	0.8	0
365	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018 , 202, 89-96	4.9	10
364	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. <i>Coronary Artery Disease</i> , 2018 , 29, 469-476	1.4	3
363	Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. <i>American Heart Journal</i> , 2018 , 201, 103-110	4.9	0
362	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005635	6	9
361	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study. <i>Circulation</i> , 2018 , 138, 712-723	16.7	64
360	Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, E348-E355	2.7	5
359	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 391-399	16.2	49
358	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 158-165	4.3	6
357	First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005-2015. <i>Heart</i> , 2018 , 104, 51-57	5.1	15
356	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018 , 283, 83-92	10.8	31
355	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018 , 196, 28-35	4.9	8
354	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 250, 49-55	3.2	4
353	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1322-1329	3	2
352	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 72, 37-43	2.1	4

351	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
350	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2231-2264	15.1	1179
349	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018 , 138, e618-e651	16.7	865
348	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. <i>New England Journal of Medicine</i> , 2018 , 379, 1107-1117	59.2	143
347	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 270, 96-101	3.2	7
346	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018 , 5, e000752	3	1
345	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018 , 50, 26-41	36.3	186
344	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009609	6	7
343	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004755	5.8	23
342	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
341	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018 , 13, e0204352	3.7	2
340	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018 , 39, 1112-1121	9.5	32
339	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2379-2388	6.7	15
338	Management of suspected acute coronary syndrome patients admitted to cardiology or non-cardiology services at Auckland City Hospital: implications for future national data collection. <i>New Zealand Medical Journal</i> , 2018 , 131, 30-39	0.8	
337	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 155-163	4.3	1
336	Cangrelor With and Without Glycoprotein 11b/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 176-185	15.1	36
335	Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	5
334	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2017 , 261, 19-25	3.1	21

333	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 1214-1226	5.5	8
332	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017 , 188, 147-155	4.9	2
331	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017 , 103, 1168-1176	5.1	25
330	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
329	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017 , 188, 156-166	4.9	8
328	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1527-1539	59.2	390
327	State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. <i>Clinical Chemistry</i> , 2017 , 63, 165-176	5.5	26
326	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017 , 63, 325-333	5.5	62
325	High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017 , 63, 307-315	5.5	16
324	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	6
323	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
322	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1689-1700	15.1	101
321	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). <i>Circulation</i> , 2017 , 136, 2440-2450	16.7	67
320	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	10
319	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017 , 12, e0182115	3.7	10
318	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017 , 38, 2813-2822	9.5	33
317	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017 , 38, 804-810	9.5	114
316	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4

315	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). <i>American Journal of Cardiology</i> , 2017 , 120, 1043-1048	3	9
314	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017 , 245, 271-276	3.2	15
313	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 813-826	15.1	58
312	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	6
311	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017 , 248, 361-368	3.2	10
310	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017 , 103, 1860-1866	5.1	39
309	Proposed new industry code on unhealthy food marketing to children and young people: will it make a difference?. <i>New Zealand Medical Journal</i> , 2017 , 130, 94-101	0.8	6
308	A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. <i>New Zealand Medical Journal</i> , 2017 , 130, 17-28	0.8	2
307	30-day mortality after percutaneous coronary intervention in New Zealand public hospitals (ANZACS-QI 18). <i>New Zealand Medical Journal</i> , 2017 , 130, 54-63	0.8	1
306	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 443-454	4.3	31
305	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the Targeted platelet Inhibition to Clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 231-42	4.3	79
304	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). <i>Circulation</i> , 2016 , 134, 1314-1324	16.7	79
303	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1667-76	5	3
302	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	2
301	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1905-13	5	27
300	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	9
299	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016 , 99, 40-55	11	61
298	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	36

297	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016 , 99, 22-39	11	42
296	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , 2016 , 133, 248-55	16.7	23
295	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 839-46	3.9	28
294	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 171, 25-32	4.9	10
293	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
292	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
291	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 596-8	15.1	20
290	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 936-947	15.1	32
289	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1582-90	9.5	235
288	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016 , 37, 412-22	9.5	15
287	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 322-323	15.1	11
286	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016 , 99, 8-21	11	47
285	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016 , 102, 1221-9	5.1	2
284	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016 , 178, 55-64	4.9	2
283	Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study. <i>Circulation</i> , 2016 , 133, 1851-60	16.7	37
282	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016 , 133, 1560-73	16.7	15
281	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016 , 178, 1-8	4.9	9
280	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2135-2144	15.1	46

279	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016 , 37, 1993-2001	9.5	77
278	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1169-1178	15.1	99
277	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation</i> , 2016 , 134, 723-33	16.7	23
276	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016 , 39, 329-37	3.3	5
275	Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	12
274	The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9). <i>New Zealand Medical Journal</i> , 2016 , 129, 23-36	0.8	6
273	Reply to letter by Kirat and KBe: Maximizing information from a 12-lead electrocardiogram. <i>International Journal of Cardiology</i> , 2015 , 197, 145-6	3.2	1
272	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the Targeted platelet inhibition to clarify the optimal strategy to medically manage Acute Coronary Syndromes trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1075-83	4.9	15
271	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2015 , 115, 1325-32	3	16
270	Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 181-183	5	27
269	ST deviations and serial changes after reperfusion therapy in patients with inferior STEMI: Relationship between inferior leads, medial chest leads and lateral leads. <i>International Journal of Cardiology</i> , 2015 , 184, 348-349	3.2	6
268	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 357-67	5.8	26
267	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015 , 170, 683-694.e3	4.9	22
266	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015 , 201, 499-507	3.2	36
265	Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. <i>JACC: Cardiovascular Imaging</i> , 2015 , 8, 1121-1129	8.4	38
264	Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. <i>Circulation</i> , 2015 , 132, 1871-9	16.7	30
263	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 771-8	3.9	35
262	High-sensitivity cardiac troponin T in stable patients undergoing pharmacological stress testing. <i>Clinical Cardiology</i> , 2015 , 38, 293-9	3.3	6

261	Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	8
260	Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002314	6	13
259	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015 , 101, 279-86	5.1	9
258	Post-operative aspartate aminotransferase levels independently predict mortality after isolated coronary artery bypass grafting. <i>IJC Metabolic & Endocrine</i> , 2015 , 6, 31-35		2
257	Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2015 , 115, 428-33	3	18
256	Resolution of ST depression after fibrinolysis can be more important than resolution of ST elevation for many patients with inferior STEMIs. <i>International Journal of Cardiology</i> , 2015 , 182, 232-4	3.2	5
255	Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 215-51	15.1	46
254	Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy). <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 266-75	5	2
253	Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). <i>JACC: Heart Failure</i> , 2014 , 2, 159-65	7.9	65
252	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
251	Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. <i>American Journal of Medicine</i> , 2014 , 127, 105-8	2.4	88
250	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014 , 168, 76-87.e1	4.9	19
249	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014 , 35, 2516-23	9.5	65
248	Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Heart</i> , 2014 , 100, 424-32	5.1	41
247	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 891-900	15.1	172
246	Republished: clinical implications of the third universal definition of myocardial infarction. <i>Postgraduate Medical Journal</i> , 2014 , 90, 502-10	2	3
245	Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1638-45	3	6
244	Importance of frailty in patients with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 1726-31	9.5	159

243	Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 285-93	6	108
242	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014 , 168, 588-96	4.9	38
241	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 246-56	4.3	12
240	Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 335-43	7.9	31
239	Universal MI definition update for cardiovascular disease. <i>Current Cardiology Reports</i> , 2014 , 16, 492	4.2	31
238	Comparison of four risk scores for contemporary isolated coronary artery bypass grafting. <i>Heart Lung and Circulation</i> , 2014 , 23, 469-74	1.8	18
237	Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1048-57	15.1	38
236	Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 936-44	3	16
235	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <i>American Heart Journal</i> , 2014 , 168, 682-9	4.9	303
234	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1006-15	27.4	285
233	A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1376-86	3.9	30
232	Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014 , 20, 516-23	3.3	3
231	Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. <i>Journal of the American Heart Association</i> , 2014 , 3,	6	7
230	Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 112-120	15.1	73
229	Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. <i>International Journal of Cardiology</i> , 2014 , 174, 90-5	3.2	0
228	Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2884-5	15.1	
227	Prognostic performance of kinetic changes of high-sensitivity troponin T in acute coronary syndrome and in patients with increased troponin without acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014 , 174, 524-9	3.2	6
226	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013 , 382, 1981-92	40	234

225	The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: implications for clinical practice. <i>International Journal of Cardiology</i> , 2013 , 170, 17-23	3.2	13
224	Rivaroxaban for the treatment of acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 917-27	4	1
223	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 678-85	3.9	47
222	Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 242-251	15.1	29
221	Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. <i>International Journal of Cardiology</i> , 2013 , 167, 1134-40	3.2	43
220	Documento de consenso de expertos. Tercera definici3n universal del infarto de miocardio. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 132.e1-132.e15	1.5	14
219	Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. <i>JACC: Heart Failure</i> , 2013 , 1, 223-9	7.9	29
218	A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. <i>Heart</i> , 2013 , 99, 1282-7	5.1	27
217	Effect of platelet inhibition with cangrelor during PCI on ischemic events. <i>New England Journal of Medicine</i> , 2013 , 368, 1303-13	59.2	560
216	Physical activity in patients with stable coronary heart disease: an international perspective. <i>European Heart Journal</i> , 2013 , 34, 3286-93	9.5	50
215	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. <i>Coronary Artery Disease</i> , 2013 , 24, 321-7	1.4	2
214	Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the universal definition of MI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 323-33	4.3	31
213	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2013 , 6, 402-9	4.5	15
212	Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. <i>Circulation</i> , 2013 , 128, 823-33	16.7	103
211	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA[CER) trial. <i>European Heart Journal</i> , 2013 , 34, 1723-31	9.5	34
210	Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. <i>Journal of the American Heart Association</i> , 2013 , 2, e000360	6	38
209	Third universal definition of myocardial infarction. <i>Srce I Krvni Sudovi</i> , 2013 , 32, 29-46		
208	Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand. <i>New Zealand Medical Journal</i> , 2013 , 126, 12-22	0.8	1

207	Response to NZMJ editorial by Dr Elana Curtis entitled Deserving of more: framing of Māori inequities in cardiovascular care remain a challenge. <i>New Zealand Medical Journal</i> , 2013 , 126, 132-3	0.8	
206	Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013 , 126, 56-65	0.8	10
205	Higher mortality in women undergoing coronary artery bypass grafting. <i>New Zealand Medical Journal</i> , 2013 , 126, 25-31	0.8	14
204	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants 2013 , 332-397		1
203	Electrocardiography in acute coronary syndromes 2012 , 110-122		
202	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2	570
201	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012 , 9, 620-33	14.8	146
200	Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012 , 163, 182-90.e4	4.9	83
199	Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. <i>American Heart Journal</i> , 2012 , 163, 563-71	4.9	32
198	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012 , 163, 768-776.e2	4.9	64
197	Biomarkers in acute coronary syndromes 2012 , 18-29		1
196	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
195	Third universal definition of myocardial infarction. <i>Circulation</i> , 2012 , 126, 2020-35	16.7	2259
194	New ST-depression: an under-recognized high-risk category of Q-complete ST-resolution after reperfusion therapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012 , 1, 210-21	4.3	4
193	Patients with circumflex occlusions miss out on reperfusion: how to recognize and manage them. <i>Current Opinion in Cardiology</i> , 2012 , 27, 327-30	2.1	8
192	The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 384-92	9.5	36
191	Third universal definition of myocardial infarction. <i>Global Heart</i> , 2012 , 7, 275-95	2.9	233
190	We should cap the health budget and spend more money on housing and food: NO. <i>Journal of Primary Health Care</i> , 2012 , 4, 339-41	0.8	

189	Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2406-8	15.1	250
188	Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 2309-16	15.1	43
187	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
186	Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. <i>American Heart Journal</i> , 2011 , 161, 450-61	4.9	25
185	Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , 2011 , 162, 613-619.e1	4.9	69
184	2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. <i>Heart Lung and Circulation</i> , 2011 , 20, 487-502	1.8	83
183	Antithrombotic therapy in ST-segment elevation myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 213-23	4	2
182	The role of lipoprotein-associated phospholipase a ₂ as a marker and potential therapeutic target in atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 132-7	6	19
181	Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)). <i>Current Atherosclerosis Reports</i> , 2011 , 13, 461-6	6	3
180	Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomaX to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), HORIZONS-AMI (thrombolysis in myocardial infarction with aspiration percutaneous coronary intervention), and the COMPELL (comparing percutaneous coronary intervention with aspirin to primary prevention in acute myocardial infarction) trials. <i>Circulation</i> , 2011 , 123, 1077-85	5	274
179	Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 769-77	5	27
178	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47	16.7	2467
177	Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. <i>Circulation</i> , 2011 , 124, 2320-8	16.7	26
176	Management of ST-elevation myocardial infarction 2011 , 474-484		
175	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. <i>Personalized Medicine</i> , 2010 , 7, 319-325	2.2	4
174	Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. <i>Circulation</i> , 2010 , 121, 2724-30	16.7	60
173	Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. <i>Circulation</i> , 2010 , 121, 853-62	16.7	28
172	Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction. <i>Circulation</i> , 2010 , 122, 463-9	16.7	26

171	aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction. <i>European Heart Journal</i> , 2010 , 31, 1845-53	9.5	56
170	Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. <i>Personalized Medicine</i> , 2010 , 7, 361-369	2.2	0
169	Rheumatic heart disease in indigenous populations. <i>Heart Lung and Circulation</i> , 2010 , 19, 273-81	1.8	44
168	Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010 , 139, 123-33	3.2	32
167	Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2010 , 159, 110-6	4.9	25
166	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TOPICUM) trial. <i>American Heart Journal</i> , 2010 , 160, 1533-4	4.9	109
165	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadib TherapY) comparing darapladib versus placebo in patients with coronary heart disease. <i>American Heart Journal</i> , 2010 , 160, 655-61	4.9	97
164	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010 , 376, 1233-43	4.0	624
163	Darapladib and its potential for plaque stabilization and prevention of cardiac events. <i>Clinical Lipidology</i> , 2010 , 5, 465-476		2
162	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI ACS: a subgroup analysis from the SYNERGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 928-35	2.7	15
161	The ATOLL trial of enoxaparin in primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2010 , 31, 2826-7	9.5	1
160	Intravenous platelet blockade with cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2330-41	59.2	480
159	Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 529-38	5.5	9
158	Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2318-29	59.2	454
157	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009 , 30, 1457-66	9.5	260
156	Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.	16.7	137
155	Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. <i>European Heart Journal</i> , 2009 , 30, 2556-7	9.5	
154	Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 1083-91	5	34

153	HORIZONS trial: a step forward for primary percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 125-9	2.5	1
152	The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an international randomized Evaluation (STEEPLE) trial. <i>American Heart Journal</i> , 2009 , 157, 125-31	4.9	9
151	Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1021-30	15.1	106
150	Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 477-86	15.1	138
149	Strategies to minimize bleeding complications of percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2009 , 24, 273-8	2.1	8
148	Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial. <i>Heart</i> , 2009 , 95, 276-82	5.1	34
147	Antithrombotic Agents: Platelet Inhibitors, Anticoagulants, and Fibrinolytics 2009 , 293-340		
146	Fibrinolysis for Acute Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2009 , 651-666		
145	Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1730-7	15.1	64
144	Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 807-14	15.1	60
143	Heart disease in Soweto: facing a triple threat. <i>Lancet, The</i> , 2008 , 371, 876-7	4.0	3
142	Acute myocardial infarction. <i>Lancet, The</i> , 2008 , 372, 570-84	4.0	466
141	Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. <i>European Heart Journal</i> , 2008 , 29, 1827-33	9.5	32
140	Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrinolysis. <i>Circulation</i> , 2008 , 118, 219-22	16.7	19
139	Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. <i>European Heart Journal</i> , 2008 , 29, 462-71	9.5	50
138	Will new higher-precision troponins lead to clarity or confusion?. <i>Current Opinion in Cardiology</i> , 2008 , 23, 292-5	2.1	14
137	Enoxaparin: a perspective on its use for coronary artery disease. <i>Aging Health</i> , 2008 , 4, 579-591		1
136	Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2008 , 14, 543-8	3.5	28

135	Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. <i>Journal of General Internal Medicine</i> , 2008 , 23, 310-6	4	37
134	Glycoprotein IIb/IIIa Inhibitors 2008 , 65-86		2
133	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. <i>Heart Rhythm</i> , 2007 , 4, 308-13	6.7	17
132	Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1362-8	15.1	665
131	Universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2173-95	15.1	1365
130	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 69, 73-83	2.7	88
129	ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 851-7	2.5	4
128	Elderly patients should not be denied fibrinolytic therapy. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 520-1		
127	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 591-602	27.4	226
126	Cardiovascular disease on a global scale: defining the path forward for research and practice. <i>European Heart Journal</i> , 2007 , 28, 2678-84	9.5	24
125	Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. <i>European Heart Journal</i> , 2007 , 28, 1066-71	9.5	73
124	Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2497-506	27.4	185
123	Universal definition of myocardial infarction. <i>European Heart Journal</i> , 2007 , 28, 2525-38	9.5	1518
122	Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. <i>Archives of Internal Medicine</i> , 2007 , 167, 239-45		439
121	Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. <i>Circulation</i> , 2007 , 115, 2549-69	16.7	507
120	Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. <i>Circulation</i> , 2007 , 115, 2570-89	16.7	398
119	Universal definition of myocardial infarction. <i>Circulation</i> , 2007 , 116, 2634-53	16.7	1953
118	Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOronary sYndromes trials. <i>American Heart Journal</i> , 2007 , 154, 313-21	4.9	14

117	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet, The</i> , 2007 , 369, 907-19	4.0	322
116	Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 249-57	4	13
115	Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. <i>Vascular Health and Risk Management</i> , 2007 , 3, 425-30	4.4	14
114	Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. <i>New England Journal of Medicine</i> , 2006 , 355, 1006-17	59.2	266
113	Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2006 , 354, 1477-88	59.2	465
112	Bivalirudin for patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 355, 2203-16	59.2	1167
111	Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2511-5	27.4	428
110	Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. <i>European Heart Journal</i> , 2006 , 27, 21-8	9.5	90
109	Risk stratification of patients with acute anterior myocardial infarction and right bundle-branch block: importance of QRS duration and early ST-segment resolution after fibrinolytic therapy. <i>Circulation</i> , 2006 , 114, 783-9	16.7	50
108	Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2. <i>Lancet, The</i> , 2006 , 367, 2061-7	4.0	60
107	A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1346-54	15.1	69
106	Coronary intervention for persistent occlusion after myocardial infarction. <i>New England Journal of Medicine</i> , 2006 , 355, 2395-407	59.2	505
105	Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. <i>American Heart Journal</i> , 2006 , 152, 1042-50	4.9	71
104	Adherence and outcomes: it's more than taking the pills. <i>Lancet, The</i> , 2005 , 366, 1989-91	4.0	34
103	Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. <i>Circulation</i> , 2005 , 112, 1992-2001	16.7	165
102	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). <i>American Heart Journal</i> , 2005 , 149, 217-26	4.9	71
101	Design and methodology of the Occluded Artery Trial (OAT). <i>American Heart Journal</i> , 2005 , 150, 627-42	4.9	50
100	Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 266-73 ^{15.1}		87

99	Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 29-38	15.1	62
98	Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 979-86	27.4	290
97	Facilitated percutaneous coronary intervention: is this strategy ready for implementation?. <i>Current Cardiology Reports</i> , 2005 , 7, 235-41	4.2	2
96	White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. <i>Circulation</i> , 2005 , 111, 1756-62	16.7	54
95	Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>Circulation</i> , 2005 , 112, 3391-9	16.7	93
94	High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2594-600	27.4	50
93	Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.. <i>Blood</i> , 2005 , 106, 902-902	2.2	1
92	PHARMAC and lack of funding for clopidogrel. <i>New Zealand Medical Journal</i> , 2005 , 119, U1808	0.8	1
91	We must use the knowledge that we have to treat patients with acute coronary syndromes. <i>Circulation</i> , 2004 , 109, 698-700	16.7	5
90	Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 1307-16	27.4	972
89	Clinical implications of the new definition of myocardial infarction. <i>British Heart Journal</i> , 2004 , 90, 99-106		101
88	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 45-54	27.4	570
87	Acute Myocardial Infarction: Fibrinolytic Therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004 , 6, 15-28	2.1	2
86	Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. <i>New England Journal of Medicine</i> , 2004 , 351, 1285-95	59.2	1464
85	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. <i>American Heart Journal</i> , 2004 , 148, 764-75	4.9	210
84	Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial. <i>American Heart Journal</i> , 2004 , 148, 810-7	4.9	13
83	Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2004 , 77, 925-31; discussion 931	2.7	94
82	Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 55-64	27.4	174

81	Missed opportunities for better health outcomes in New Zealand. <i>New Zealand Medical Journal</i> , 2004 , 117, U1002	0.8	
80	International variation in the use of evidence-based medicines for acute coronary syndromes. <i>European Heart Journal</i> , 2003 , 24, 2133-41	9.5	28
79	Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. <i>European Heart Journal</i> , 2003 , 24, 172-81	9.5	33
78	Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 201-7		45
77	Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1380-6	15.1	201
76	Candesartan and heart failure: the allure of CHARM. <i>Lancet, The</i> , 2003 , 362, 754-5	4.0	36
75	Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?. <i>Lancet, The</i> , 2003 , 362, 755-7	4.0	31
74	Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase. <i>American Heart Journal</i> , 2003 , 145, 95-102	4.9	27
73	Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002 , 90, 54-7	3	14
72	Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 433-9	6.1	140
71	Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. <i>European Heart Journal</i> , 2002 , 23, 399-404	9.5	20
70	Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. <i>Journal of Hypertension</i> , 2002 , 20, 2513-7	1.9	7
69	Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2130-5	27.4	88
68	Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 777-88	4	12
67	Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. <i>Lancet, The</i> , 2002 , 359, 189-98	4.0	796
66	Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. <i>American Heart Journal</i> , 2002 , 144, 81-8	4.9	50
65	Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. <i>American Journal of Cardiology</i> , 2001 , 88, 558-61	3	8
64	One-year survival following early revascularization for cardiogenic shock. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 190-2	27.4	437

63	Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 56-63	15.1	96
62	Management of unstable angina. Guidelines 2000. <i>Medical Journal of Australia</i> , 2001 , 174, 423-424	4	
61	Door-to-needle times: Room for improvement and need for continuous audit. <i>EMA - Emergency Medicine Australasia</i> , 2000 , 12, 91-94	1.5	
60	Debate: Should the elderly receive thrombolytic therapy or primary angioplasty?. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2000 , 1, 150-154		5
59	Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000 , 107, 245-53	3.7	132
58	The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolized: methods and design. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 10, 241-6	5.1	18
57	Thrombolytic therapy in the elderly. <i>Lancet, The</i> , 2000 , 356, 2028-30	4.0	125
56	Low-molecular-weight heparin and platelet glycoprotein IIb/IIIa receptor blockade in the treatment of acute coronary syndromes: complementary or competing therapies?. <i>Journal of Invasive Cardiology</i> , 2000 , 12 Suppl A, 6A-13A	0.7	
55	Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. <i>New England Journal of Medicine</i> , 1999 , 341, 625-34	59.2	1960
54	Antithrombin agents as adjuncts to thrombolytic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 1999 , 8, 159-66	5.1	1
53	Direct thrombin inhibitors as adjuncts to thrombolytic therapy. <i>Current Cardiology Reports</i> , 1999 , 1, 184-212	2.1	2
52	Usefulness of the presenting electrocardiogram in predicting successful reperfusion with streptokinase in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1999 , 83, 164-8	3	38
51	Stent deformation following simulated side-branch dilatation: a comparison of five stent designs. <i>Catheterization and Cardiovascular Interventions</i> , 1999 , 47, 258-64	2.7	105
50	Future of reperfusion therapy for acute myocardial infarction. <i>Lancet, The</i> , 1999 , 354, 695-7	4.0	18
49	Long-term survival and valve-related complications in young women with cardiac valve replacements. <i>Circulation</i> , 1999 , 99, 2669-76	16.7	124
48	Is thrombin a pharmacological target during reperfusion?. <i>Blood Coagulation and Fibrinolysis</i> , 1999 , 10 Suppl 1, S55-7	1	
47	Thrombolytic eligibility. <i>Australian and New Zealand Journal of Medicine</i> , 1998 , 28, 518-24		1
46	Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. <i>Australian and New Zealand Journal of Medicine</i> , 1998 , 28, 551-4		12

45	Low molecular weight heparins in acute ischaemic syndromes. <i>Australian and New Zealand Journal of Medicine</i> , 1998 , 28, 555-7		1
44	New antiplatelet agents. <i>Australian and New Zealand Journal of Medicine</i> , 1998 , 28, 558-64		2
43	The corrected TIMI frame count. The new gold standard?. <i>Australian and New Zealand Journal of Medicine</i> , 1998 , 28, 569-73		10
42	Thrombolysis for acute myocardial infarction. <i>Circulation</i> , 1998 , 97, 1632-46	16.7	149
41	Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , 1998 , 7, 811-21	5.9	2
40	Applying the open artery theory: use of predictive survival markers. <i>European Heart Journal</i> , 1998 , 19, 1132-9	9.5	36
39	Should all occluded infarct-related arteries be opened?. <i>European Heart Journal</i> , 1997 , 18, 1207-9	9.5	19
38	Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. <i>American Heart Journal</i> , 1997 , 133, 630-9	4.9	63
37	Is heparin of value in the management of acute myocardial infarction?. <i>Cardiovascular Drugs and Therapy</i> , 1997 , 11, 111-9	3.9	6
36	Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 317-319	5.1	3
35	Coronary Artery Patency and Survival in Clinical Trials. <i>Journal of Thrombosis and Thrombolysis</i> , 1997 , 4, 239-250	5.1	1
34	Comparison of case fatality in smokers and non-smokers after acute cardiac event. <i>BMJ: British Medical Journal</i> , 1997 , 315, 992-3		22
33	Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. <i>Circulation</i> , 1997 , 96, 2155-61	16.7	168
32	Clinical Trials of Direct Thrombin Inhibitors in Acute Ischaemic Syndromes. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 364-366	7	10
31	Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 364-6	7	1
30	Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. <i>Drugs and Aging</i> , 1996 , 8, 237-44	4.7	8
29	Left ventricular function following thrombolytic therapy for myocardial infarction. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995 , 22, 173-9	3	2
28	Lifting the smoke-screen: the enigma of better outcome in smokers after myocardial infarction. <i>American Journal of Cardiology</i> , 1995 , 75, 278-9	3	9

27	Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression. <i>Heart</i> , 1995 , 73, 500-5	5.1	10
26	Evaluation of paradoxical beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker@paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 1222-9	15.1	182
25	Angioplasty versus bypass surgery. <i>Lancet, The</i> , 1995 , 346, 1174-5	4.0	14
24	Effects of thrombolytic therapy on left ventricular function and the importance of long-term patency of the infarct-related artery. <i>Clinical Science</i> , 1995 , 88, 21-4	6.5	2
23	Thrombolytic therapy for acute myocardial infarction: where are we now? Where should we go?. <i>Chinese Medical Journal</i> , 1995 , 108, 462-5	2.9	
22	Selecting a thrombolytic agent. <i>Cardiology Clinics</i> , 1995 , 13, 347-54	2.5	3
21	Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. <i>Circulation</i> , 1995 , 91, 1923-8	16.7	343
20	Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. <i>Circulation</i> , 1994 , 89, 61-7	16.7	185
19	Aspirin or warfarin for non-rheumatic atrial fibrillation?. <i>Lancet, The</i> , 1994 , 343, 683-4	4.0	15
18	Allergic Reactions to Streptokinase. <i>BioDrugs</i> , 1994 , 2, 415-420		6
17	Factors affecting outcome after recovery from myocardial infarction. <i>Annual Review of Medicine</i> , 1994 , 45, 325-39	17.4	18
16	Comparative tolerability profiles of thrombolytic agents. A review. <i>Drug Safety</i> , 1993 , 8, 19-29	5.1	9
15	Issues raised by GUSTO. <i>Australian and New Zealand Journal of Medicine</i> , 1993 , 23, 739-41		1
14	Hirudin and Hirulog. <i>Australian and New Zealand Journal of Medicine</i> , 1993 , 23, 769-70		1
13	Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. <i>Pharmacoeconomics</i> , 1993 , 3, 192-204	4.4	7
12	After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. <i>Circulation</i> , 1993 , 88, 2097-103	16.7	136
11	Reperfusion injury - a reply to Keith Fox. <i>Cardiovascular Research</i> , 1992 , 26, 660-661	9.9	3
10	Remodelling of the heart after myocardial infarction. <i>Australian and New Zealand Journal of Medicine</i> , 1992 , 22, 601-6		5

9	Thrombolytic therapy for patients with myocardial infarction presenting after six hours. <i>Lancet, The</i> , 1992 , 340, 221-2	40	25
8	Heart failure: to digitalise or not? The view against. <i>Australian and New Zealand Journal of Medicine</i> , 1992 , 22, 626-30		2
7	Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. <i>Heart</i> , 1990 , 64, 177-81	5.1	51
6	GISSI-2 and the heparin controversy. <i>Lancet, The</i> , 1990 , 336, 297-8	40	45
5	The management of myocardial infarction: an update. <i>Comprehensive Therapy</i> , 1990 , 16, 11-5		
4	Acute myocardial infarction: a true medical emergency. <i>New Zealand Medical Journal</i> , 1989 , 102, 281-3	0.8	1
3	Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. <i>New England Journal of Medicine</i> , 1987 , 317, 850-5	59.2	586
2	Liver disease induced by perhexiline maleate. <i>Medical Journal of Australia</i> , 1982 , 2, 9-10	4	3
1	Coronary Artery Bypass Grafting 240-255		